Norges Bank
NMRA icon

Norges Bank’s Neumora Therapeutics NMRA Stock Holding History

Norges Bank’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110,000
Closed -$1.17M – 1813
2024
Q4 		$1.17M Hold
110,000
– – ﹤0.01% 1745
2024
Q3 		$1.45M Hold
110,000
– – ﹤0.01% 1695
2024
Q2 		$1.08M Hold
110,000
– – ﹤0.01% 1806
2024
Q1 		$1.51M Buy
110,000
+60,000
+120% +$970K ﹤0.01% 1759
2023
Q4 		$853K Hold
50,000
– – ﹤0.01% 1875
2023
Q3 		$706K Buy
+50,000
New +$625K ﹤0.01% 1907

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Norges Bank's NMRA Position: Q1 2025 in Review

Norges Bank sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 110,000 shares — an estimated $1.17M sold.

Norges Bank first reported a position in NMRA in Q3 2023 and held it in 6 quarters. The position peaked at $1.51M in Q1 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Norges Bank reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 110,000 Neumora Therapeutics shares in Q1 2025, an estimated $1.17M.
  • Norges Bank first reported a position in Neumora Therapeutics in Q3 2023 and held it in 6 quarters.
  • Norges Bank's Neumora Therapeutics position peaked at $1.51M in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.